866-997-4948(US-Canada Toll Free)

Adenosine Receptor A3 (ADORA3)-Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Oct 2017

Category :

Pharmaceutical

No. of Pages : 71 Pages

Adenosine Receptor A3 (ADORA3)-Pipeline Review, H2 2017

Summary

According to the recently published report Adenosine Receptor A3 (ADORA3)-Pipeline Review, H2 2017; Adenosine Receptor A3 (ADORA3) pipeline Target constitutes close to 18 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes.

Adenosine Receptor A3 (ADORA3)-The adenosine A3 receptor, also known as ADORA3, is an adenosine receptor. Adenosine A3 receptors are G protein-coupled receptors that mediates a sustained cardioprotective function during cardiac ischemia. It is involved in the inhibition of neutrophil degranulation in neutrophil mediated tissue injury, it mediate both cell proliferation and cell death. A3 adenosine receptor (A3AR) is the only adenosine subtype to be over expressed in inflammatory and cancer cells, thus making it a potential target for therapy.

The report Adenosine Receptor A3 (ADORA3)-Pipeline Review, H2 2017 outlays comprehensive information on the Adenosine Receptor A3 (ADORA3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Adenosine Receptor A3 (ADORA3) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 1, 8 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Ophthalmology, Gastrointestinal, Immunology, Genito Urinary System And Sex Hormones, Musculoskeletal Disorders, Toxicology, Cardiovascular, Central Nervous System, Dermatology, Hematological Disorders, Male Health, Metabolic Disorders and Respiratory which include indications Glaucoma, Rheumatoid Arthritis, Chemotherapy Induced Peripheral Neuropathy, Non-Alcoholic Steatohepatitis (NASH), Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Arthritis, Asthma, Atopic Dermatitis, Chronic Obstructive Pulmonary Disease (COPD), Colon Cancer, Diabetic Nephropathy, Erectile Dysfunction, Glomerulonephritis, Hepatocellular Carcinoma, Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), Irritable Bowel Syndrome, Kidney Fibrosis, Lupus Erythematosus, Melanoma, Neuropathic Pain, Non Alcoholic Fatty Liver Disease (NAFLD), Ocular Hypertension, Open-Angle Glaucoma, Osteoarthritis, Plaque Psoriasis (Psoriasis Vulgaris), Prostate Cancer, Psoriasis, Pulmonary Fibrosis, Stroke and Uveitis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Adenosine Receptor A3 (ADORA3)
- The report reviews Adenosine Receptor A3 (ADORA3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Adenosine Receptor A3 (ADORA3) targeted therapeutics and enlists all their major and minor projects
- The report assesses Adenosine Receptor A3 (ADORA3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Adenosine Receptor A3 (ADORA3) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Adenosine Receptor A3 (ADORA3)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Adenosine Receptor A3 (ADORA3) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Adenosine Receptor A3 (ADORA3)-Overview
Adenosine Receptor A3 (ADORA3)-Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Adenosine Receptor A3 (ADORA3)-Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Adenosine Receptor A3 (ADORA3)-Companies Involved in Therapeutics Development
Can-Fite BioPharma Ltd
Huons Global Co Ltd
Adenosine Receptor A3 (ADORA3)-Drug Profiles
ACN-1052-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CF-602-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FM-101-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FM-1101-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FM-1102-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FM-1103-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FM-1202-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FM-1203-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FM-1301-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FM-1302-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HU-010-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LJ-1888-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LJ-2698-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
namodenoson-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PBF-1650-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PBF-677-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
piclidenoson-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize Adenosine A3 Receptor for Chemotherapy Induced Peripheral Neuropathy-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Adenosine Receptor A3 (ADORA3)-Dormant Products
Adenosine Receptor A3 (ADORA3)-Discontinued Products
Adenosine Receptor A3 (ADORA3)-Product Development Milestones
Featured News & Press Releases
Oct 17, 2017: Can-Fite Issued Patent in Korea for Piclidenoson in the Treatment of Psoriasis
Oct 16, 2017: Can-Fite to Present at 2017 AASLD Liver Meeting Conference in Washington, D.C.
Oct 09, 2017: Can-Fite CEO Dr. Pnina Fishman to Present as Expert Speaker at NASH Summit Europe in Frankfurt, Germany on October 12, 2017
Aug 23, 2017: Can-Fite Receives Milestone Payment From CKD Pharmaceuticals its Distribution Partner in Korea
Aug 09, 2017: Can-Fite Completes Patient Enrolment for its Phase II Study of Namodenoson in the Treatment of Liver Cancer
Aug 07, 2017: Can-Fite Successfully Completes Human Cardiodynamic Safety Trial for Piclidenoson
Jul 17, 2017: Can-Fites Phase II NAFLD/NASH Trial with Namodenoson Set to Commence Patient Enrollment Following Conclusion of Successful Clinical Investigator Meeting
Jun 08, 2017: Can-Fite Concludes Successful Clinical Investigator Meeting for its ACRobat Phase III Trial of Piclidenoson in the Treatment of Rheumatoid Arthritis
Jun 05, 2017: Can-Fite Establishes Clinical Advisory Board for NAFLD/NASH
Jun 01, 2017: New Preclinical Data on Can-Fites Namodenoson to be Presented at 1st International Conference on Fatty Liver in Seville, Spain on June 2, 2017
May 16, 2017: Can-Fite Files Clinical Trial Application in Canada for Piclidenoson Ahead of Upcoming Acrobat Rheumatoid Arthritis Phase III Study
May 03, 2017: Can-Fites Liver Protective Drug Namodenoson Enters Phase II Trial for Treatment of NAFLD/NASH
Apr 25, 2017: Can-Fites Phase III ACRobat Trial in Rheumatoid Arthritis Approved by Institutional Review Board
Feb 28, 2017: New Preclinical Data Show Can-Fites Namodenoson (CF102) Prevents Progression of Liver Fibrosis
Feb 08, 2017: Can-Fite Gears Up for ACRobat, its Phase III Trial of Piclidenoson in Rheumatoid Arthritis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Indications, H2 2017
Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Investigation by Universities/Institutes, H2 2017
Products under Investigation by Universities/Institutes, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Pipeline by Can-Fite BioPharma Ltd, H2 2017
Pipeline by Huons Global Co Ltd, H2 2017
Dormant Projects, H2 2017
Discontinued Products, H2 2017

List of Figures
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Top 10 Indications, H2 2017
Number of Products by Mechanism of Actions, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *